The International ALLIANCE COVID-19 Treatment Study

We are seeking Australian-based participants for the International ALLIANCE COVID-19 Treatment Study.

The National Institute of Integrative Medicine is seeking expressions of interest from individuals who live in Australia, display symptoms of COVID-19 and are planning to be tested. We also welcome expressions of interest from those that have tested positive to COVID-19 in the last 7 days.

This trial will assess the effectiveness of an integrative medical approach to preventing the progression of COVID-19 with a combination of medications and supplements.

Investigators:
Dr Taufiq Binjemain (MD, NIIM GP)
AProf Dr Karin Ried (PhD, NIIM Research Director)
Dr Avni Sali (MD, NIIM Director)

The Trial has ethics and TGA approval and is registered on the ANZ clinical trial registry (www.anzctr.org.au) ACTRN12620000557932.

Therapies* to prevent progression of COVID-19 – a multicentre international randomised trial
Arm 1: HCQ, AZM, Zinc (ref 1 & 2), Vit D (ref 3), Vit B12
Arm 2: HCQ, AZM, Zinc (ref 1 & 2), Vit D (ref 3), Vit B12 + Vit C (IVC & oral) (ref 4 & 5)

Supporting efficacy in the treatment of COVID19 with 65-94% better outcomes, incl prevention of death.

References

1) The Zelenko Protocol + 94 studies https://c19study.com

2) HCQ for COVID-19 – a meta-analysis of 294 studies https://hcqmeta.com/
Latest update 28 May 2021: Evidence for HCQ to be effective in treating COVID-19:
2 quadrillion to 1 (p = 0.00000000000000053).

  • HCQ for COVID-19: real-time meta analysis of 246 studies
    Covid Analysis, Oct 20, 2020 (Version 111, May 28, 2021 — added Million)
  • 100% of the 29 early treatment studies report a positive effect (13 statistically significant in isolation).
  • Random effects meta-analysis with pooled effects using the most serious outcome reported shows 66% improvement for the 29 early treatment studies (RR 0.34 [0.24-0.49]). Results are similar after exclusion based sensitivity analysis: 67% (RR 0.33 [0.24-0.44]), and after restriction to 20 peer-reviewed studies: 65% (RR 0.35 [0.25-0.47]). Restricting to the 6 RCTs shows 46% improvement (RR 0.54 [0.33-0.86]). Restricting to the 13 mortality results shows 75% lower mortality (RR 0.25 [0.16-0.40]).
  • Late treatment is less successful, with only 71% of the 167 studies reporting a positive effect. Very late stage treatment is not effective and may be harmful, especially when using excessive dosages.

3) Brighthope Ian, Sali Avni, Ried Karin: Vitamin-D and COVID-19: time for the profession to take a stand. AIMED Jan 2021, https://pubmed.ncbi.nlm.nih.gov/33520645/

4) Simmons WF, Smith, RG: Vitamin C and Coronavirus: Not a Vaccine; Just a Humble Cure. OMNS May 2 2020, OMNS May 4, 2020, http://www.orthomolecular.org/resources/omns/v16n28.shtml

5) Holford P: Vitamin C Cuts COVID Deaths by Two-Thirds OMNS, Oct 13, 2020, http://orthomolecular.org/resources/omns/v16n50.shtml

 

For more information about the trial or to submit an expression of interest, click below.

Expression of interest: research@niim.com.au

Subject heading: Alliance Covid-19 Trial

 

Learn more about our current Vitamin D study:

http://niim.com.au/vitDstudy